Search
Zhongsheng Pharmaceutical: Phase III Clinical Trial for Innovative Obesity Drug RAY1225 Begins with First Participant Enrollment
3 week ago /
Read about 0 minute
Author：小编
Zhongsheng Pharmaceutical's holding subsidiary, Zhongsheng Ruichuang, has successfully enrolled and administered the first participant in the Phase III clinical trial for RAY1225 injection, a groundbreaking peptide drug designed to treat obesity and overweight. RAY1225, possessing dual agonist activity for both GLP-1 and GIP receptors, represents a novel structural peptide drug with exclusive global intellectual property rights. The trial, which has received ethical approval from a leading institution, is now gradually being launched at multiple research centers nationwide.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
